3 Top Nuclear Stocks to Buy Right Now

Cameco: revenue $3.4B (+11% YoY) supported by a 34% rise in uranium prices, with a 16.9% net margin, D/E 0.14 and a 49% stake in Westinghouse, giving exposure across the uranium-to-reactor fuel cycle. BWX Technologies: revenue $3.19B (+18% YoY), EPS +20% YoY, net margin 10.3%, and a strong position in small modular reactor (SMR) technology via the BANR prototype. Constellation Energy: operates 21 U.S. reactors (~>20% of the fleet), revenue +8% YoY (2025), adjusted operating EPS +8%, net margin 9.1%, dividend yield ~0.83% with announced consecutive 10% DPS increases; geopolitical risks around the Strait of Hormuz and Iran tensions are cited as additional demand tailwinds for nuclear investments.

Analysis

Vertical integration and balance-sheet optionality are the real structural advantages here — firms that can finance multi-year reactor builds or hold fuel-cycle positions through cyclical spot moves will extract outsized value versus asset-light pure plays. Expect pressure on midstream fuel services (conversion/enrichment) and heavy forgings to create bottle-necks that re-rate companies owning or controlling those steps; conversely, firms without balance-sheet capacity will see tender margins compress as financing-led EPCs capture contractor surplus.

Time horizons split cleanly: commodity-driven uplifts (uranium spot, utility contracting) play out over months-to-two-years and are sensitive to secondary supply flows and geopolitics, while commercial SMR and large reactor capex cycles are multi-year (3–7+ years) and hinge on demonstrator timelines, permitting, and long-lead capital. Key reversal triggers to watch are a re-integration of Russian-derived fuel into markets, a material utility destocking cycle, or multi-quarter slippage in SMR demonstrators which would knock forward order expectations.

The market consensus prices a lot of “technology optionality” into smaller-cap SMR hopefuls; a more surgical approach is to own companies where that optionality is non-core upside while core businesses cash-flow through any demonstration delays. Practical monitoring filters that will give early warning: utility contracting cadence, NRC/DOE licensing milestones, large forgings lead times, and Brookfield-style project finance announcements — any of which can compress or expand perceived optionality in weeks, not years.

Key Decisions for Investors

• BWXT — Tactical long via capped call spread (12–18 month LEAP call debit + higher-strike call sold) to capture SMR/defense optionality while limiting premium exposure. Target 30–50% upside if demonstrator milestones or large naval/SMR orders materialize; max loss limited to net premium. Monitor: DOE/NRC milestone calendar and any announced fabrication awards as stop-loss/triggers to pare.
• CCJ — Buy-dated (9–18 month) calls funded by selling near-term calls to create a financed LEAP position; this expresses long uranium/fuel-cycle exposure but forces roll discipline against spot volatility. Rationale: captures upside if utility contracting continues while funding short-term theta decay; downside risk is material if secondary supply returns — cap position size to implied vol spikes >40%.
• CEG — Core long equity (12–24 months) for regulated nuclear cashflow and dividend-growth optionality; finance with short-dated call writes to improve yield. Expect steady mid-single-digit upside plus income in base-case; hedge regulatory/execution risk by shorting a merchant gas-generator ETF sized to offset ~30–40% of thermal dispatch exposure.
• Relative-value pair — Long BWXT / Short pure-play SMR juniors (small-cap SMR developers) sized 1:1 by market cap exposure. Mechanism: capture value transfer if demonstrators favor experienced OEMs and cause consolidation; if demonstrator risk crystallizes negative, this pair limits broad sector beta. Exit or rebalance on first major SMR order award or demonstrator failure announcement.